Alimera’s Q2-2018 Revenues Increase 5 Percent

August 3, 2018: By Jon Swedien

Alimera Sciences posted Q2-2018 net revenues of $10.9 million, a 5 percent increase compared with Q2-2017, the company reported July 30.

The Alpharetta, Georgia-based company markets Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for diabetic macular edema (DME). Iluvien is Alimera’s only commercial product.

The company’s US net revenues in Q2-2018 were $8 million, down 1 percent compared with the $8.1 million in US net revenues the company reported in Q2-2017. The decrease was caused by lower distributor orders for Q2-2018 compared with Q2-2017, despite growth in US end-user demand, Alimera said.

Alimera CEO Dan Myers said Q2-2018 was the company’s highest quarter in both global sales and end user demand. Net revenues from Alimera’s international segment increased by 26 percent to about $2.9 million for Q2-2018 compared with about $2.3 million for Q2-2017.

Iluvien received US approval in September 2014 and is also available in 17 other countries.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT